Recent report suggested that TP53-mutated AML are highly susceptible to treatment with hypomethylating agents32, which have been shown to activate the expression of TE and the downstream interferon cascade, leading to cancer cell death7,8,33. The gene discussed is TP53; the disease is acute myeloid leukemia.